Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis.

Animals Anti-Inflammatory Agents, Non-Steroidal / chemistry Cyclooxygenase 2 / metabolism Cyclooxygenase 2 Inhibitors / chemistry Cystic Fibrosis / drug therapy Humans Inflammation / drug therapy Molecular Structure Nitric Oxide / chemistry
CINODs COX-2 Cystic fibrosis Inflammation

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Jan 2021
Historique:
received: 04 06 2020
revised: 27 10 2020
accepted: 28 10 2020
pubmed: 11 11 2020
medline: 23 4 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.

Identifiants

DOI: 10.1016/j.ejmech.2020.112983 PMID: 33168231
pubmed: 33168231
pii: S0223-5234(20)30955-7
doi: 10.1016/j.ejmech.2020.112983
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Cyclooxygenase 2 Inhibitors 0
Nitric Oxide 31C4KY9ESH
Cyclooxygenase 2 EC 1.14.99.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

112983

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sara Consalvi (S)

Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.

Giovanna Poce (G)

Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.

Carla Ghelardini (C)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Via Schiff 6, Sesto Fiorentino, 50019, Florence, Italy.

Lorenzo Di Cesare Mannelli (L)

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Via Schiff 6, Sesto Fiorentino, 50019, Florence, Italy.

Paola Patrignani (P)

Department of Neuroscience, Imaging and Clinical Sciences, And Center for Advanced Studies and Technology (CAST), School of Medicine, G. D'Annunzio University, Chieti, Italy.

Annalisa Bruno (A)

Department of Neuroscience, Imaging and Clinical Sciences, And Center for Advanced Studies and Technology (CAST), School of Medicine, G. D'Annunzio University, Chieti, Italy.

Maurizio Anzini (M)

Department of Biotechnology, Chemistry, And Pharmacy, DoE 2018-2022, University of Siena, 53100, Siena, Italy.

Vincenzo Calderone (V)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Alma Martelli (A)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Lara Testai (L)

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Antonio Giordani (A)

Formerly Rottapharm at the Present Consultant, Italy.

Mariangela Biava (M)

Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy. Electronic address: mariangela.biava@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Anti-inflammatoires non stéroïdiens › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Cyclooxygenase 2 › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Anti-inflammatoires non stéroïdiens › Inhibiteurs des cyclooxygénases › Inhibiteurs de la cyclooxygénase 2 › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies néonatales › Mucoviscidose › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Therapeutic potential for coxibs-nitric oxide...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Oxydes d'azote › Monoxyde d'azote › Therapeutic potential for coxibs-nitric oxide...